Literature DB >> 26279118

Efficient Transfection of Phosphorothioate Oligodeoxyribonucleotides by lipofectamine2000 into Different Bacteria.

Zhou Chen, Yue Hu, Jingru Meng, Mingkai Li, Zheng Hou, Ying Zhou, Xiaoxing Luo, Xiaoyan Xue1.   

Abstract

Antisense technology has been a promising strategy for combating infectious diseases caused by multi-drug resistant bacterial strains, but the poor cellular uptake and transfection efficiency of these "antisense antibiotics" is strangling the development of antisense RNA therapeutics. This study was aimed at evaluating the cellular uptake characteristics and transfection efficiency of antisense phosphorothioate oligodeoxyribonucleotides (PS-ODN) in bacterial cells mediated by LipofectamineTM 2000 (LF2000). The size and surface morphology of LF2000/ODN nanoparticle were determined by dynamic light scattering and transmission electron microscope. Then the characteristics of cellular uptake were studied by flow cytometry analysis, and antibacterial efficacy of LF2000/ODN nanoparticle targeting rpoD, an RNA polymerase primary σ70, was tested by analyzing the growth inhibition of targeted bacteria and by RT-PCR analysis of the target genes. And the results indicated that the size of the spherical nanoparticle obtained was about 120 nm with a zeta potential about -5 mV, and the encapsulation efficiency of PS-ODN was about 95%. The cellular uptake efficiencies of LF2000/ODN nanoparticle by extended-spectrum β -lactamase-producing Escherichia coli (ESBLs-E. coli) and E. coli were 40.1% and 48.5% in a time-independent manner, while 76.7% and 79.3% by meticillin-resistant Staphylococcus aureus (MRSA) and S. aureus in a time-dependent manner. Interestingly, the uptake process was not altered by the incubation temperature. After being incubated with LF2000/ODN, the growth of tested bacteria were significantly retarded and the transcription of rpoD was inhibited. Our research not only provided a basis for further studies on delivery systems for antisense antibiotics, but also highlighted a novel cellular uptake mechanism of nanoparticle.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26279118     DOI: 10.2174/1567201812666150817123528

Source DB:  PubMed          Journal:  Curr Drug Deliv        ISSN: 1567-2018            Impact factor:   2.565


  5 in total

Review 1.  Advances in therapeutic bacterial antisense biotechnology.

Authors:  John P Hegarty; David B Stewart
Journal:  Appl Microbiol Biotechnol       Date:  2017-12-05       Impact factor: 4.813

2.  Bolaamphiphile-based nanocomplex delivery of phosphorothioate gapmer antisense oligonucleotides as a treatment for Clostridium difficile.

Authors:  John P Hegarty; Jacek Krzeminski; Arun K Sharma; Diana Guzman-Villanueva; Volkmar Weissig; David B Stewart
Journal:  Int J Nanomedicine       Date:  2016-08-01

3.  Co-delivery of free vancomycin and transcription factor decoy-nanostructured lipid carriers can enhance inhibition of methicillin resistant Staphylococcus aureus (MRSA).

Authors:  Alan Hibbitts; Ainhoa Lucía; Inés Serrano-Sevilla; Laura De Matteis; Michael McArthur; Jesús M de la Fuente; José A Aínsa; Fabrice Navarro
Journal:  PLoS One       Date:  2019-09-03       Impact factor: 3.240

4.  Amphipathic dendritic poly-peptides carrier to deliver antisense oligonucleotides against multi-drug resistant bacteria in vitro and in vivo.

Authors:  Zhou Chen; Yue Hu; Xinggang Mao; Dan Nie; Hui Zhao; Zheng Hou; Mingkai Li; Jingru Meng; Xiaoxing Luo; Xiaoyan Xue
Journal:  J Nanobiotechnology       Date:  2022-04-02       Impact factor: 10.435

5.  Loop-armed DNA tetrahedron nanoparticles for delivering antisense oligos into bacteria.

Authors:  Yue Hu; Zhou Chen; Xinggang Mao; Mingkai Li; Zheng Hou; Jingru Meng; Xiaoxing Luo; Xiaoyan Xue
Journal:  J Nanobiotechnology       Date:  2020-08-04       Impact factor: 10.435

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.